Marker Therapeutics, Inc. (NASDAQ:MRKR – Get Free Report)’s stock price fell 0.8% during mid-day trading on Tuesday . The stock traded as low as $4.61 and last traded at $4.67. 11,244 shares were traded during trading, a decline of 45% from the average session volume of 20,446 shares. The stock had previously closed at $4.71.
Analyst Upgrades and Downgrades
Separately, LADENBURG THALM/SH SH assumed coverage on shares of Marker Therapeutics in a research note on Tuesday, April 30th. They issued a “buy” rating and a $11.00 target price on the stock.
View Our Latest Analysis on MRKR
Marker Therapeutics Trading Down 0.8 %
Marker Therapeutics (NASDAQ:MRKR – Get Free Report) last released its earnings results on Wednesday, May 15th. The company reported ($0.27) earnings per share for the quarter. The business had revenue of $1.24 million during the quarter. Marker Therapeutics had a negative net margin of 142.62% and a negative return on equity of 39.89%. On average, research analysts expect that Marker Therapeutics, Inc. will post -1.64 EPS for the current fiscal year.
Institutional Trading of Marker Therapeutics
An institutional investor recently raised its position in Marker Therapeutics stock. International Assets Investment Management LLC raised its position in Marker Therapeutics, Inc. (NASDAQ:MRKR – Free Report) by 1,000.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,000 shares of the company’s stock after acquiring an additional 10,000 shares during the quarter. International Assets Investment Management LLC owned approximately 0.12% of Marker Therapeutics worth $60,000 at the end of the most recent reporting period. 22.39% of the stock is owned by institutional investors.
Marker Therapeutics Company Profile
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.
Recommended Stories
- Five stocks we like better than Marker Therapeutics
- ESG Stocks, What Investors Should Know
- Chipotle Mexican Grill Stock Split: Where Does it Go From Here?
- How to invest in blue chip stocks
- Arm Holdings and Micron: Top 2 AI Stocks to Buy and Hold
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Best Buy Stock May Be Best Bought Before the Holiday Season
Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.